C-CHHWorexin-1 antagonist, dopamine transporter inhibitor, glioblastoma
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Characterize the pharmacokinetics, safety, and tolerability of RDC5 in healthy volunteers.
Single-dose Phase 1 clinical trial at multiple dose levels in healthy volunteers.
ClinicalTrials.gov record describes a Phase 1 pharmacokinetics, safety, and tolerability study first published in December 2013.
Develop an atypical dopamine transporter inhibitor for fatigue and narcolepsy, with potential relevance to effort-related motivational dysfunction.
Small-molecule atypical dopamine transporter inhibition; CT-005404 was characterized in rodent effort-based choice tasks and inflammatory/neurochemical models.
Preclinical publication reported that CT-005404 reversed tetrabenazine- and IL-1β-induced reductions in lever pressing and increased progressive-ratio lever pressing when administered alone.
In rodent models, CT-005404 showed pro-motivational effects and was described as a potential avenue for treating motivational dysfunctions in humans.
Develop an orexin-1 receptor antagonist for substance use disorders and anxiety, with the company aiming to generate data sets suitable for partnering with mid-size to large pharma.
Small-molecule orexin-1 receptor antagonist therapeutic program.
Listed in TheraCryf's pipeline as one of three named programs.
Develop SFX-01 for glioblastoma as part of TheraCryf's oncology and behavioural brain disorders pipeline.
Enteric-coated stabilized sulforaphane formulation, described as d,l-sulforaphane stabilized in an alpha-cyclodextrin complex; evaluated in a randomized, double-blind, placebo-controlled dose-escalation Phase 1 study in healthy male participants.
Phase 1 safety, tolerability, and pharmacokinetic study of enteric-coated SFX-01 tablets was published in 2025.
SFX-01 was reported as safe and tolerable over 7 days. Treatment-emergent adverse events were mostly mild gastrointestinal events. Pharmacokinetics showed rapid absorption consistent with enteric coating, with minimal evidence of accumulation.